Expert Review of Cardiovascular Therapy最新文献_第10页

Optimal use of intravenous landiolol in acute cardiac care. 静脉滴注兰地洛尔在急性心脏护理中的最佳应用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2277354

Sofia Bezati, Antonios Boultadakis, Ioannis Ventoulis, Eftihia Polyzogopoulou, John T Parissis

{"title":"Optimal use of intravenous landiolol in acute cardiac care.","authors":"Sofia Bezati, Antonios Boultadakis, Ioannis Ventoulis, Eftihia Polyzogopoulou, John T Parissis","doi":"10.1080/14779072.2023.2277354","DOIUrl":"10.1080/14779072.2023.2277354","url":null,"abstract":"Introduction: B-blockers are regarded as beneficial pharmacologic agents in cardiac care, but their role in the acute setting remains ambiguous. Increasing evidence supports the important role of landiolol in critical care, a highly cardioselective intravenous b-blocker with rapid onset of action and short elimination time. Among its most valuable properties, which may aid to overcome special reservations related to b-blocker therapy in the acute setting, landiolol has a potent negative chronotropic effect while at the same time it exhibits a mild negative inotropic effect.Areas covered: This expert opinion review aims to present basic pharmacologic aspects of landiolol and provide current clinical research focused on its efficacy and safety.Expert opinion: Landiolol is a valuable and safe pharmacologic agent in acute cardiac care. Japanese and European guidelines have incorporated its use for the management of atrial tachyarrhythmia in patients with cardiac dysfunction. Although emerging clinical trials have experimented its use in patients with sustained ventricular tachycardia/fibrillation, acute myocardial infarction undergoing primary percutaneous intervention and in patients with septic cardiomyopathy, more studies are needed in order to establish its value in such cardiac conditions.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"855-866"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary management of infective endocarditis in pregnancy. 妊娠期感染性心内膜炎的现代治疗。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2276891

Ailís Pollock, Thomas J Kiernan

{"title":"Contemporary management of infective endocarditis in pregnancy.","authors":"Ailís Pollock, Thomas J Kiernan","doi":"10.1080/14779072.2023.2276891","DOIUrl":"10.1080/14779072.2023.2276891","url":null,"abstract":"Introduction: Infective endocarditis (IE) during pregnancy is a rare condition that is associated with a high level of morbidity and mortality. The epidemiology, diagnosis, treatment, and prognosis have changed significantly in the last two decades. The declining incidence of rheumatic heart disease, improved life expectancy with congenital heart disease, advances in cardiac surgery and cardiac devices, rise in resistant microorganisms, complications of the opioid epidemic, and increasing maternal age are some of the many factors contributing to these changes.Areas covered: This article explores existing literature on the topic including case reports, case series, registry data, and clinical guidelines. The focus of this article is the evolving epidemiology, predisposing factors and preventative measures, clinical presentation, investigation, management, and potential complications of IE in pregnancy.Expert opinion: Robust prospective data on the management of IE in pregnancy is lacking, and obtaining these data will be very challenging. It is imperative that international registries are used to provide data on best clinical practices and inform future clinical guidelines. Multimodal imaging should be incorporated in the investigation of complicated cases. A multidisciplinary approach to the management of this rare and life-threatening condition is essential to ensure the best outcomes for both the mother and the fetus.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"839-854"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure. 心力衰竭患者中钠-葡萄糖共转运蛋白2抑制剂的不良事件和药物相互作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2273900

Claudia Stöllberger, Josef Finsterer, Birke Schneider

{"title":"Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure.","authors":"Claudia Stöllberger, Josef Finsterer, Birke Schneider","doi":"10.1080/14779072.2023.2273900","DOIUrl":"10.1080/14779072.2023.2273900","url":null,"abstract":"Introduction: Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug-drug interactions (DDI) seems low. Safety-data derive mainly from diabetes-patients. This review aims to summarize adverse-events (AE) and DDI of the SGLT2-I dapagliflozin, empagliflozin and sotagliflozin in patients with CHF.Areas covered: Literature-search-terms in PubMed were 'adverse event/drug-drug interaction' and 'heart failure AND 'dapagliflozin' OR 'empagliflozin' OR 'sotagliflozin.'AEreported in randomized controlled trials (RCT) comprisegenitaland urinary-tract infections, hypotension, ketoacidosis, renal impairment, hypoglycemia, limb-amputations, Fournier's gangrene, bone-fractures, hepatopathy, pancreatitis, diarrhea, malignancy and venous thromboembolism. Their incidence is largely unknown, since they were not consistently evaluated in RCT of CHF. Further AE from meta-analyses, pharmacovigilance reports, case-series and case-reports include erythrocytosis, hypertriglyceridemia, myopathy, sarcopenia, skin problems, ventricular tachycardia, and urinary retention. The maximal observation period of RCT in CHF was 26 months.DDI were mainly studied in healthy volunteers for 3-8 days. In CHF or diabetes-patients, DDI were reported with interleukin-17-inhibitors, linezolid, lithium, tacrolimus, valproate, angiotensin-receptor-neprilysin-inhibitors and intravenous iron.Expert opinion: Guidelines recommend treatment with SGLT2-I for CHF but no data on AE during long-term therapy and only little information on DDI are available, which stresses the need for further research. Evidence-based recommendations for ketoacidosis-prevention are desirable.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"803-816"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized biomechanical insights in atrial fibrillation: opportunities & challenges. 房颤的个性化生物力学见解:机遇与挑战。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2273896

Åshild Telle, Clarissa Bargellini, Yaacoub Chahine, Juan C Del Álamo, Nazem Akoum, Patrick M Boyle

{"title":"Personalized biomechanical insights in atrial fibrillation: opportunities & challenges.","authors":"Åshild Telle, Clarissa Bargellini, Yaacoub Chahine, Juan C Del Álamo, Nazem Akoum, Patrick M Boyle","doi":"10.1080/14779072.2023.2273896","DOIUrl":"10.1080/14779072.2023.2273896","url":null,"abstract":"Introduction: Atrial fibrillation (AF) is an increasingly prevalent and significant worldwide health problem. Manifested as an irregular atrial electrophysiological activation, it is associated with many serious health complications. AF affects the biomechanical function of the heart as contraction follows the electrical activation, subsequently leading to reduced blood flow. The underlying mechanisms behind AF are not fully understood, but it is known that AF is highly correlated with the presence of atrial fibrosis, and with a manifold increase in risk of stroke.Areas covered: In this review, we focus on biomechanical aspects in atrial fibrillation, current and emerging use of clinical images, and personalized computational models. We also discuss how these can be used to provide patient-specific care.Expert opinion: Understanding the connection betweenatrial fibrillation and atrial remodeling might lead to valuable understanding of stroke and heart failure pathophysiology. Established and emerging imaging modalities can bring us closer to this understanding, especially with continued advancements in processing accuracy, reproducibility, and clinical relevance of the associated technologies. Computational models of cardiac electromechanics can be used to glean additional insights on the roles of AF and remodeling in heart function.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"817-837"},"PeriodicalIF":1.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50157467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of cardiac sarcoidosis: histological evidence vs. imaging. 心脏结节病的诊断：组织学证据与影像学。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2266367

Shinichi Kurashima, Takeshi Kitai, Andrew Xanthopoulos, John Skoularigis, Filippos Triposkiadis, Chisato Izumi

{"title":"Diagnosis of cardiac sarcoidosis: histological evidence vs. imaging.","authors":"Shinichi Kurashima, Takeshi Kitai, Andrew Xanthopoulos, John Skoularigis, Filippos Triposkiadis, Chisato Izumi","doi":"10.1080/14779072.2023.2266367","DOIUrl":"10.1080/14779072.2023.2266367","url":null,"abstract":"Introduction: The prognosis for cardiac sarcoidosis (CS) remains unfavorable. Although early and accurate diagnosis is crucial, the low detection rate of endomyocardial biopsy makes accurate diagnosis challenging.Areas covered: The Heart Rhythm Society (HRS) consensus statement and the Japanese Circulation Society (JCS) guidelines are two major diagnostic criteria for the diagnosis of CS. While the requirement of positive histology for the diagnosis in the HRS criteria can result in overlooked cases, the JCS guidelines advocate for a group of 'clinical' diagnoses based on advanced imaging, including cardiovascular magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography, which do not require histological evidence. Recent studies have supported the usefulness of clinical diagnosis of CS. However, other evidence suggests that clinical CS may sometimes be inaccurate. This article describes the advantages and disadvantages of the current diagnostic criteria for CS, and typical imaging and clinical courses.Expert opinion: The diagnosis of clinical CS has been made possible by recent developments in multimodality imaging. However, it is still crucial to look for histological signs of sarcoidosis in other organs in addition to the endomyocardium. Additionally, phenotyping based on clinical manifestations such as heart failure, conduction abnormality or ventricular arrhythmia, and extracardiac abnormalities is clinically significant.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"693-702"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41112649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bivalirudin in acute coronary syndromes. 双缬氨酸治疗急性冠状动脉综合征。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-13 DOI: 10.1080/14779072.2023.2273902

Mattia Galli, Marco Bernardi, Luis Ortega-Paz, Roberto Nerla, Domenico D'Amario, Francesco Franchi, Giuseppe Biondi-Zoccai, Dominick J Angiolillo

{"title":"Bivalirudin in acute coronary syndromes.","authors":"Mattia Galli, Marco Bernardi, Luis Ortega-Paz, Roberto Nerla, Domenico D'Amario, Francesco Franchi, Giuseppe Biondi-Zoccai, Dominick J Angiolillo","doi":"10.1080/14779072.2023.2273902","DOIUrl":"10.1080/14779072.2023.2273902","url":null,"abstract":"Introduction: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).Areas covered: Despite showing a superior safety profile compared with unfractionated heparin (UFH), bivalirudin is not considered the anticoagulant of choice in ACS patients undergoing PCI, mainly because of an increased rate of acute stent thrombosis (ST) shown by several randomized controlled trials (RCTs), in addition to limited availability in certain countries and increased costs. However, RCTs on bivalirudin have been characterized by several confounding factors hindering the interpretation of its safety and efficacy compared with UFH among the spectrum of ACS patients. Furthermore, a significant body of evidence has demonstrated that the risk of acute ST can be mitigated by a full-dose infusion regimen following PCI, without compromising the favorable safety profile compared to UFH.Expert opinion: In light of the increased understanding of the prognostic relevance of bleeding events and the excellent safety profile of bivalirudin, recent trial evidence may allow for this anticoagulant agent to reemerge and have a more prominent role in the management of ACS patients undergoing PCI.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"901-911"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Genotype-guided dual antiplatelet therapy in cerebrovascular disease: assessing the risk and benefits for ethnic populations. 基因型引导的双抗血小板治疗脑血管疾病：评估种族人群的风险和益处。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-13 DOI: 10.1080/14779072.2023.2245754

Kasim Qureshi, Muhammad U Farooq, Philip B Gorelick

引用次数: 0

The use of digital health in heart rhythm care. 数字健康在心律护理中的应用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-06-23 DOI: 10.1080/14779072.2023.2226868

Donald P Tchapmi, Chris Agyingi, Antoine Egbe, Gregory M Marcus, Jean Jacques Noubiap

{"title":"The use of digital health in heart rhythm care.","authors":"Donald P Tchapmi, Chris Agyingi, Antoine Egbe, Gregory M Marcus, Jean Jacques Noubiap","doi":"10.1080/14779072.2023.2226868","DOIUrl":"10.1080/14779072.2023.2226868","url":null,"abstract":"Introduction: Digital health is a broad term that includes telecommunication technologies to collect, share and manipulate health information to improve patient health and health care services. With the growing use of wearables, artificial intelligence, machine learning, and other novel technologies, digital health is particularly relevant to the field of cardiac arrhythmias, with roles pertinent to education, prevention, diagnosis, management, prognosis, and surveillance.Areas covered: This review summarizes information on the clinical use of digital health technology in arrhythmia care and discusses its opportunities and challenges.Expert opinion: Digital health has begun to play an essential role in arrhythmia care regarding diagnostics, long-term monitoring, patient education and shared decision making, management, medication adherence, and research. Despite remarkable advances, integrating digital health technologies into healthcare faces challenges, including patient usability, privacy, system interoperability, physician liability, analysis and incorporation of the huge amount of real-time information from wearables, and reimbursement. Successful implementation of digital health technologies requires clear objectives and deep changes to existing workflows and responsibilities.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":"21 8","pages":"553-563"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10306130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing atrial fibrillation in COVID-19: exploring the role of interleukin-6 receptor antagonists. 预防新冠肺炎心房颤动：探讨白细胞介素-6受体拮抗剂的作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264774

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

引用次数: 0

Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease. 监测冠状动脉疾病预后、疾病严重程度和治疗效果的生物标志物。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264779

Armand N Yazdani, Michaela Pletsch, Abraham Chorbajian, David Zitser, Vikrant Rai, Devendra K Agrawal

{"title":"Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.","authors":"Armand N Yazdani, Michaela Pletsch, Abraham Chorbajian, David Zitser, Vikrant Rai, Devendra K Agrawal","doi":"10.1080/14779072.2023.2264779","DOIUrl":"10.1080/14779072.2023.2264779","url":null,"abstract":"Introduction: Coronary Artery Disease (CAD) is a prevalent condition characterized by the presence of atherosclerotic plaques in the coronary arteries of the heart. The global burden of CAD has increased significantly over the years, resulting in millions of deaths annually and making it the leading health-care expenditure and cause of mortality in developed countries. The lack of cost-effective strategies for monitoring the prognosis of CAD warrants a pressing need for accurate and efficient markers to assess disease severity and progression for both reducing health-care costs and improving patient outcomes.Area covered: To effectively monitor CAD, prognostic biomarkers and imaging techniques play a vital role in risk-stratified patients during acute treatment and over time. However, with over 1,000 potential markers of interest, it is crucial to identify the key markers with substantial utility in monitoring CAD progression and evaluating therapeutic interventions. This review focuses on identifying and highlighting the most relevant markers for monitoring CAD prognosis and disease severity. We searched for relevant literature using PubMed and Google Scholar.Expert opinion: By utilizing the markers discussed, health-care providers can improve patient care, optimize treatment plans, and ultimately reduce health-care costs associated with CAD management.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"675-692"},"PeriodicalIF":1.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41115171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0